540 likes | 562 Views
Spleen-Preserving Distal Pancreatectomy. Traian Dumitrascu Dan Setlacec Center of General Surgery and Liver Transplant Fundeni Clinical Institute Bucharest. Introduction. Spleen-preserving distal pancreatectomy (SPDP): an alternative procedure to distal pancreatectomy with splenectomy
E N D
Spleen-Preserving Distal Pancreatectomy Traian Dumitrascu Dan Setlacec Center of General Surgery and Liver Transplant Fundeni Clinical Institute Bucharest
Introduction • Spleen-preserving distal pancreatectomy (SPDP): • an alternative procedure to distal pancreatectomy with splenectomy • for benign/ low-grade malignant tumors of the pancreatic body • removal of the spleen during distal pancreatectomy was associated with increased postoperative morbidity • the role of the spleen in immunity was clearly demonstrated by experimental and clinical studies Shoup, Arch Surg, 2002; Ionescu, Chirurgia, 2003; Fernandez-Cruz, HPB (Oxford), 2005; Tiron & Vasilescu, Chirurgia, 2008; Dumitrascu, Dig Surg, 2012; Lacatus, Chirurgia, 2013
Introduction • WHY Spleen-preservation? • Spleen play a key role in: • mechanical filtration, which removes senescent erythrocytes • maintenance of normal immune function and host defenses against certain types of infectious agents • prevention of infection in children • avoid overwhelming postsplenectomy infection (OPSI): S. pneumoniae, H. influenze, N. meningitidis • major site of production for the opsonins: properdin and tuftsin (bactericide and anti tumor activity) Removal of the spleen results in loss of both the immunologic and filtering functions Ionescu, Chirurgia, 2003; Tiron & Vasilescu, Chirurgia, 2008;Lacatus, Chirurgia, 2013 Vasilescu, Splina. De la laparoscopie la chirurgia robotica si inapoi, Ed. Medicala, 2016
Introduction • What are the risks following splenectomy? • Infectious risks- OPSI • The highest risk in the first 2 years • Mortality – up to 46% • Non-infectious risks : • Arterial events • Thromboembolic events • Pulmonary hypertension • Developing cancer Dragomir, Chirurgia, 2016
SPDP • PRO: • the role of the spleen in immunity • better endocrine function preservation • removal of the spleen during distal pancreatectomy was associated with increased postoperative morbidity • the major concern after splenectomy is overwhelming postsplenectomy infection (OPSI) • CONS: • more technically challenging • increased morbidity Shoup, Arch Surg, 2002; Ionescu, Chirurgia, 2003; Fernandez-Cruz, HPB (Oxford), 2005; Tiron & Vasilescu, Chirurgia, 2008; Dumitrascu, Dig Surg, 2012; Lacatus, Chirurgia, 2013
Anatomy - arteries Mikami, Diseases of the Pancreas, Springer-Verlag, 2008
Anatomy - veins Mikami, Diseases of the Pancreas, Springer-Verlag, 2008 7
Technique Warshaw, Arch Surg, 1988; Warshaw, J Hepatobiliary Pancreat Sci, 2010 8
Technique Fernandez-Cruz, Atlas of Advanced Operative Surgery, Elsevier, 2013 9
Technique Fernandez-Cruz, Atlas of Advanced Operative Surgery, Elsevier, 2013 10
Technique Kimura, Surgery, 1996
Technique Fernandez-Cruz, Atlas of Advanced Operative Surgery, Elsevier, 2013 12
Technique Spleen SA PV SV Pancreas Head VMS SPDP – final aspect
Technique Fundeni Clinical Institute: 41 SPDP – 6 minimally-invasive (2 laparoscopic; 4 robotic)
Indications T Ferrone & Warshaw, Ann Surg, 2011
Indications Serous cystadenoma
Indications Neuroendocrine neoplasm G1
Indications Solid pseudopapillary tumor
Indications Grawitz metastasis
Indications 2012 23
Morbidity • Early morbidity • 22 - 46% • Splenectomy rate (1.9 – 5.2%) Ferrone & Warshaw, Ann Surg, 2011; Tien, Ann Surg Oncol, 2010; Shoup, Arch Surg, 2002
Long-term Outcome • Perigastric varices – up to 30% 29
Discussion • Estimated blood loss higher for: • SPDP (Ma JP, Chinese Med J, 2011) • DPS (Shoup M, Arch Surg, 2002) • No difference (Nau P, Gastroenterology Research and Practice, 2009; Lee SE, J Korean Med Sci, 2008; Tezuka K, Dig Surg, 2012; Tsiouris A, HPB, 2011; Kimura W, J Hepatobiliary Pancreat Sci, 2010; Choi SH, Surg Endosc, 2012) • Overall complications rate higher for: • DPS (Carrere N, World J Surg, 2006; Choi SH, Surg Endosc, 2012) • No difference (Nau P, Gastroenterology Research and Practice, 2009; Lee SE, J Korean Med Sci, 2008; Tezuka K, Dig Surg, 2012; Tsiouris A, HPB, 2011; Kimura W, J Hepatobiliary Pancreat Sci, 2010) • Infectious complications higher for • DPS (Shoup M, Arch Surg, 2002; Benoist S, JACS, 1999; Choi SH, Surg Endosc, 2012) • No difference (Nau P, Gastroenterology Research and Practice, 2009; Lee SE, J Korean Med Sci, 2008; Tezuka K, Dig Surg, 2012; Tsiouris A, HPB, 2011; Kimura W, J Hepatobiliary Pancreat Sci, 2010) • Diabetes rate is lower for • SPDP (Fernandez-Cruz L, HPB, 2005; Govil S, Br J Surg, 1999) • no differences (Carrere N, World J Surg, 2006; Lee SE, J Korean Med Sci, 2008; Kimura W, J Hepatobiliary Pancreat Sci, 2010) T IVC Mp SMV PV SMV SMA CT SMA
T IVC Mp SMV PV SMV SMA CT SMA
T IVC Mp SMV PV SMV SMA CT SMA
Discussion T Ma JP, Chinese Med J, 2011 IVC Mp Lee SE, J Korean Med Sci, 2008 SMV PV SMV SMA Tsiouris A, HPB, 2011 CT SMA Kimura W, J Hepatobiliary Pancreat Sci, 2010
Fundeni Clinical Institute Experience • Indications • Postoperative morbidity - infectious • Long-term results
Patients & Methods Fundeni Clinical Institute 2000 – 2015 41 patients with SPDP
Results • Median age: 41 years (18 – 76) • Sex ratio F/M = 2.4/1 (29/12) • Median BMI: 25 kg/m2 (19 – 42) • Symptoms: • Present – 37 pts (90%) • Epigastric pain – 27 pts • Hypoglycemia – 9 pts • Absent – 4 pts
Results • Pancreas texture: soft – 35 pts (85%) • Median operative time: • 150 min (70 – 330)
Results • Blood loss: • Median intraoperative blood loss: 150 ml (50 – 300 ml) • 1 pts with intraoperative transfusions • Postoperative transfusions – 6 pts (14%)
Results • Morbidity – 14 pts (34%) • Mortality – 0 pts • POPF – 13 pts (32%): • Grade A – 6 pts • Grade B – 5 pts • Grade C – 2 pts • Postoperative hemorrhage – 5 pts (12%) • Delayed gastric empting – 5 pts (12%)
Results • Re-laparotomy for complications – 5 pts (12%): • POPF grade C – 2 pts (2 pts with POH) • PO Hemorrhage alone – 2 pts • Abdominal abscess – 1 pt • Cave: 1 pt – splenectomy
Results • Median tumor diameter: 3.5 cm (0.4 – 14) • Pathology: • Benign/ low-grade malignant – 37 pts • Malignant – 4 pts
Results • Serous cystadenoma – 6 pts • Mucinous cystadenoma – 3 pts • NET G1/ G2 – 15 pts • Non-functional: 5 pts • Insulinoma: 9 pts • Gastrinoma: 1 pt • Solid pseudopapillary tumor – 6 pt • Focal chronic pancreatitis – 5 pt • Malignant – 3 pt • Metastases of other neoplasia – 1 pts
Results • Median follow-up: 65 months (1 – 177) • Functional results (34 pts): • Diabetes mellitus – 6 pts (17%) • Exocrine pancreatic insufficiency – 2 pts (6%)
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, Dig Surg, 2012
T IVC Mp SMV PV SMV SMA CT SMA
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, J Hepatobiliary Pancreat Sci, 2014
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, J Hepatobiliary Pancreat Sci, 2014
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, J Hepatobiliary Pancreat Sci, 2014
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, J Hepatobiliary Pancreat Sci, 2014
T IVC Mp SMV PV SMV SMA CT SMA Dumitrascu, J Hepatobiliary Pancreat Sci, 2014